Search results
Results from the WOW.Com Content Network
Cancer of unknown primary origin (CUP) is a cancer that is determined to be at the metastatic stage at the time of diagnosis, but a primary tumor cannot be identified. A diagnosis of CUP requires a clinical picture consistent with metastatic disease and one or more biopsy results inconsistent with a tumor cancer.
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of uncertain or unknown behavior. [7] Malignant neoplasms are also simply known as cancers and are the focus of oncology.
This is a shortened version of the second chapter of the ICD-9: Neoplasms. It covers ICD codes 140 to 239. The full chapter can be found on pages 101 to 144 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
Lung cancer is the most diagnosed and deadliest cancer worldwide, with 2.2 million cases in 2020 resulting in 1.8 million deaths. [3] Lung cancer is rare in those younger than 40; the average age at diagnosis is 70 years, and the average age at death 72. [2] Incidence and outcomes vary widely across the world, depending on patterns of tobacco use.
The incidence of bronchiolo-alveolar carcinoma has been reported to vary from 4–24% of all lung cancer patients. [23] An analysis of Surveillance epidemiology and End results registry ( SEER) by Read et al. revealed that although the incidence of BAC has increased over the past two decade it still constitutes less than 4% of NSCLC in every ...
Adenocarcinoma of the lung is currently the most common type of lung cancer in "never smokers" (lifelong nonsmokers). [10] Adenocarcinomas account for about 40% of lung cancers. Historically, adenocarcinoma was more often seen peripherally in the lungs than SCLC and squamous-cell lung cancer, both of which tended to be more often centrally located.
Small cell lung cancer is often treated as a systematic disease due to its tendency for early dissemination, [4] thus, instead of the traditional TNM staging system, the Veterans' Administration Lung Study Group (VALSG) introduced a simplified 2-stage system in the 1950s to divide small cell lung cancer into limited stage and extensive stage. [7]